Skip to main content
Top
Published in:

Open Access 16-05-2024 | Neurofibromatosis Type 1 | Research

Outcomes of surgical revascularization for pediatric moyamoya disease and syndrome

Authors: Jason H. Boulter, Nicholas S. Szuflita, Robert F. Keating, Suresh N. Magge

Published in: Child's Nervous System | Issue 8/2024

Login to get access

Abstract

Purpose

Moyamoya disease and syndrome represent rare entities characterized by progressive stenosis and/or occlusion of the intracranial blood vessels. We present our series of patients with moyamoya disease and syndrome stratified by underlying disease and analyze differences in presentation and outcome following surgical revascularization.

Methods

This was an Institutional Review Board (IRB) approved, retrospective review of all patients surgically revascularized by the senior author (SNM) while at Children’s National Hospital in Washington, DC. Demographic data, presenting symptoms and severity, surgical details, and functional and radiographic outcomes were obtained and analyzed for differences among the underlying cohorts of moyamoya disease and syndrome as well as by unilateral or bilateral disease and index or non-index surgeries.

Results

Twenty-two patients were identified with the following underlying diseases: six with idiopathic moyamoya disease, six with sickle cell anemia, five with trisomy 21, and five with neurofibromatosis type 1. Thirty hemispheres were revascularized with a significantly reduced rate of stroke from 3.19 strokes/year (SD = 3.10) to 0.13 strokes/year (SD = 0.25), p = 0.03. When analyzed by underlying cause of moyamoya syndrome, patients with neurofibromatosis type 1 were found to be significantly less likely than the other subtypes of moyamoya syndrome to have had either a clinical stroke (0.0% neurofibromatosis type 1 vs. 100.0% sickle cell, 60.0% trisomy 21, or 83.3% moyamoya disease, p < 0.01) or radiographic stroke (0.0% neurofibromatosis type 1 vs. 100.0% sickle cell, 60.0% trisomy 21, or 83.3% moyamoya disease, p < 0.01) at time of presentation. Patients with moyamoya syndrome associated with sickle cell disease were more likely to present with clinical and radiographic strokes. Additionally, patients with bilateral disease demonstrated no difference in final functional outcome compared to patients with unilateral disease (mRS 0.73 (SD = 1.33) vs. 1.29 (SD = 1.60), p = 0.63).

Conclusion

Indirect surgical revascularization decreases stroke risk for pediatric patients with different forms of moyamoya disease and moyamoya syndrome. Additionally, these data suggest that sickle cell anemia-associated moyamoya syndrome may represent a more aggressive variant, while neurofibromatosis type 1 may represent a more benign variant.
Literature
1.
go back to reference DeVeber GA, Kirton A, Booth FA et al (2017) Epidemiology and outcomes of arterial ischemic stroke in children: the Canadian Pediatric Ischemic Stroke Registry. Pediatr Neurol 69:58–70CrossRefPubMed DeVeber GA, Kirton A, Booth FA et al (2017) Epidemiology and outcomes of arterial ischemic stroke in children: the Canadian Pediatric Ischemic Stroke Registry. Pediatr Neurol 69:58–70CrossRefPubMed
2.
go back to reference Rafay MF, Shapiro KA, Surmava A-M et al (2020) Spectrum of cerebral arteriopathies in children with arterial ischemic stroke. Neurology 94(23):e2479–e2490CrossRefPubMedPubMedCentral Rafay MF, Shapiro KA, Surmava A-M et al (2020) Spectrum of cerebral arteriopathies in children with arterial ischemic stroke. Neurology 94(23):e2479–e2490CrossRefPubMedPubMedCentral
3.
go back to reference Smith ER, Scott RM (2008) Progression of disease in unilateral moyamoya syndrome. Neurosurg Focus 24(2):E17CrossRefPubMed Smith ER, Scott RM (2008) Progression of disease in unilateral moyamoya syndrome. Neurosurg Focus 24(2):E17CrossRefPubMed
4.
go back to reference Kelly ME, Bell-Stephens TE, Marks MP, Do HM, Steinberg GK (2006) Progression of unilateral moyamoya disease: a clinical series. Cerebrovasc Dis 22:109–115CrossRefPubMed Kelly ME, Bell-Stephens TE, Marks MP, Do HM, Steinberg GK (2006) Progression of unilateral moyamoya disease: a clinical series. Cerebrovasc Dis 22:109–115CrossRefPubMed
5.
go back to reference Houkin K, Abe H, Yoshimoto T, Takahashi A (1996) Is, “unilateral” moyamoya disease different from moyamoya disease? J Neurosurg 85(5):772–776CrossRefPubMed Houkin K, Abe H, Yoshimoto T, Takahashi A (1996) Is, “unilateral” moyamoya disease different from moyamoya disease? J Neurosurg 85(5):772–776CrossRefPubMed
6.
go back to reference Uchino K, Johnson SC, Becker KJ, Tirschwell DL (2005) Moyamoya disease in Washington State and California. Neurology 65(6):956–958CrossRefPubMed Uchino K, Johnson SC, Becker KJ, Tirschwell DL (2005) Moyamoya disease in Washington State and California. Neurology 65(6):956–958CrossRefPubMed
7.
go back to reference Gadgil N, Lam S, Pyarali M, Paldino M, Pan I-W, Dauser RC (2018) Indirect revascularization with the dural inversion technique for pediatric moyamoya disease: 20-year experience. J Neurosurg Pediatr 22(5):541–549CrossRefPubMed Gadgil N, Lam S, Pyarali M, Paldino M, Pan I-W, Dauser RC (2018) Indirect revascularization with the dural inversion technique for pediatric moyamoya disease: 20-year experience. J Neurosurg Pediatr 22(5):541–549CrossRefPubMed
8.
go back to reference Griessenauer CJ, Lebensburger JD, Chua MH et al (2015) Encephaloduroarteriosynangiosis and encephalomyoarteriosynagiosis for treatment of moyamoya syndrome in pediatric patients with sickle cell disease. J Neurosurg 16(1):64–73 Griessenauer CJ, Lebensburger JD, Chua MH et al (2015) Encephaloduroarteriosynangiosis and encephalomyoarteriosynagiosis for treatment of moyamoya syndrome in pediatric patients with sickle cell disease. J Neurosurg 16(1):64–73
9.
go back to reference Santoro C, Rocco FD, Kossorotoff M et al (2017) Moyamoya syndrome in children with neurofibromatosis type 1: Italian-French experience. Am J Med Genet 173(6):1521–1530CrossRefPubMed Santoro C, Rocco FD, Kossorotoff M et al (2017) Moyamoya syndrome in children with neurofibromatosis type 1: Italian-French experience. Am J Med Genet 173(6):1521–1530CrossRefPubMed
10.
go back to reference Koss M, Scott RM, Irons MB, Smith ER, Ullrich NJ (2013) Moyamoya syndrome associated with neurofibromatosis type 1: perioperative and long-term outcome after surgical revascularization. J Neurosurg Pediatr 11(4):377–488CrossRef Koss M, Scott RM, Irons MB, Smith ER, Ullrich NJ (2013) Moyamoya syndrome associated with neurofibromatosis type 1: perioperative and long-term outcome after surgical revascularization. J Neurosurg Pediatr 11(4):377–488CrossRef
11.
go back to reference Scott RM, Smith JL, Robertson R, Madsen JR, Soriano SG, Rockoff MA (2004) Long-term outcome in children with moyamoya syndrome after cranial revascularization by pial synangiosis. J Neurosurg 100(2):142–149PubMed Scott RM, Smith JL, Robertson R, Madsen JR, Soriano SG, Rockoff MA (2004) Long-term outcome in children with moyamoya syndrome after cranial revascularization by pial synangiosis. J Neurosurg 100(2):142–149PubMed
12.
go back to reference Kim S-K, Cho B-K, Phi JH et al (2010) Pediatric moyamoya disease: an analysis of 410 consecutive cases. Ann Neurol 68(1):92–101CrossRefPubMed Kim S-K, Cho B-K, Phi JH et al (2010) Pediatric moyamoya disease: an analysis of 410 consecutive cases. Ann Neurol 68(1):92–101CrossRefPubMed
13.
go back to reference Newman S, Boulter JH, Malcolm JG, Pradilla I, Pradilla G (2020) Outcomes in patients with moyamoya syndrome and sickle cell disease: a systematic review. World Neurosurgery 135:165–170CrossRefPubMed Newman S, Boulter JH, Malcolm JG, Pradilla I, Pradilla G (2020) Outcomes in patients with moyamoya syndrome and sickle cell disease: a systematic review. World Neurosurgery 135:165–170CrossRefPubMed
14.
go back to reference Newman S, McMahon JT, Boulter JH, Malcolm JG, Revuelta Barbero JM, Chern JJ, Barrow DL, Pradilla G (2022) Revascularization is associated with a reduced stroke risk in patients with sickle cell-associated moyamoya syndrome. Neurosurgery 90(4):441–446CrossRefPubMed Newman S, McMahon JT, Boulter JH, Malcolm JG, Revuelta Barbero JM, Chern JJ, Barrow DL, Pradilla G (2022) Revascularization is associated with a reduced stroke risk in patients with sickle cell-associated moyamoya syndrome. Neurosurgery 90(4):441–446CrossRefPubMed
15.
go back to reference Webb J, Kwiatkowski JL (2013) Stroke in patients with sickle cell disease. Expert Rev Hematol 6(3):301–316CrossRefPubMed Webb J, Kwiatkowski JL (2013) Stroke in patients with sickle cell disease. Expert Rev Hematol 6(3):301–316CrossRefPubMed
16.
go back to reference Moritani T, Numaguchi Y, Lemer NB, Rozans MK, Robinson AE, Hiwatashi A, Westesson PL (2004) Sickle cell cerebrovascular disease: usual and unusual findings on MR imaging and MR angiography. Clin Imaging 28(3):173–186CrossRefPubMed Moritani T, Numaguchi Y, Lemer NB, Rozans MK, Robinson AE, Hiwatashi A, Westesson PL (2004) Sickle cell cerebrovascular disease: usual and unusual findings on MR imaging and MR angiography. Clin Imaging 28(3):173–186CrossRefPubMed
17.
go back to reference Hankinson TC, Bohman L-E, Heyer G et al (2008) Surgical treatment of moyamoya syndrome in patients with sickle cell anemia: outcome following encephaloduroarteriosynangiosis. J Neurosurg 1:211–216 Hankinson TC, Bohman L-E, Heyer G et al (2008) Surgical treatment of moyamoya syndrome in patients with sickle cell anemia: outcome following encephaloduroarteriosynangiosis. J Neurosurg 1:211–216
18.
go back to reference Ghosh PS, Rothner AD, Emch TM, Friedman NR, Moodley M (2013) Cerebral vasculopathy in children with neurofibromatosis type 1. J Child Neurol 28(1):95–101CrossRefPubMed Ghosh PS, Rothner AD, Emch TM, Friedman NR, Moodley M (2013) Cerebral vasculopathy in children with neurofibromatosis type 1. J Child Neurol 28(1):95–101CrossRefPubMed
Metadata
Title
Outcomes of surgical revascularization for pediatric moyamoya disease and syndrome
Authors
Jason H. Boulter
Nicholas S. Szuflita
Robert F. Keating
Suresh N. Magge
Publication date
16-05-2024
Publisher
Springer Berlin Heidelberg
Published in
Child's Nervous System / Issue 8/2024
Print ISSN: 0256-7040
Electronic ISSN: 1433-0350
DOI
https://doi.org/10.1007/s00381-024-06393-w

Other articles of this Issue 8/2024

Child's Nervous System 8/2024 Go to the issue

Advances in Alzheimer's

Alzheimer's research and care is changing rapidly. Keep up with the latest developments from key international conferences, together with expert insights on how to integrate these advances into practice.

This content is intended for healthcare professionals outside of the UK.

Supported by:
  • Lilly
Developed by: Springer Healthcare IME
Learn more